OX40 costimulation acts synergistically with GVAX boosting the elimination of tumor cells in a murine melanoma model

Abstract

Event Abstract Back to Event OX40 costimulation acts synergistically with GVAX boosting the elimination of tumor cells in a murine melanoma model Andrea J. Manrique Rincón1, 2, Camila Marques Beraldo1, Jessica Marcelino Toscaro1, Anna C. Pereira Vieira De Carvalho1 and Marcio C. Bajgelman1, 2* 1 National Center For Research in Energy and Materials – CNPEM, Brazilian Biosciences National Laboratory– LNBio , Brazil 2 University of Campinas, Medical School, Brazil GM-CSF-expressing tumor cell-based vaccine (GVAX) induces a potent antitumor response and is considered as a gold standard to compare efficacy of new strategies that are being developed to produce specific anti-tumor immunity. Although GVAX has surprising results in animal models, there is no comparable success in the clinic. This observation can be associated to the complexity of the immune system and low immunogenicity of tumor cells that may be protected by immunosuppressive mechanisms which mediate activation and proliferation of effectors lymphocytes. The costimulatory TNFSF receptors can modulate phenotypic properties of T cell, reducing the activation threshold, inducing a greater level of proliferation and preventing cell death after activation. In this work, we evaluate the anti tumor effect of modified B16F10 irradiated tumor cells expressing TNFRSF4, also know as OX40 ligand (CD134), which receptor is expressed on the surface of activated T cells and play a role in the maintenance of the immune response.We have performed in vivo assays in C57BL/6 mice that were challenged with wild type B16 F10 tumor cells and treated with modified B16F10 irradiated cells. We compare tumor progression in 4 groups of mice divided according to the modified B16 F10 they received (A) PBS, (B) GVAX, (C) OX40L and (D) combination of GVAX and OX40L. Our data suggests that OX40L induces the same reduction in tumor mass as the gold standard GVAX, and the combination of the two approaches provides a synergistic effect, enhancing the elimination of tumor cells. Acknowledgements The authors acknowledge to the funding agency FAPESP. Process Number 2013/02041-6. Keywords: Immunotherapy, Tumor cell vaccine, Melanoma, GVAX, OX40 Ligand Conference: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología, Medellin, Colombia, 13 Oct - 16 Oct, 2015. Presentation Type: Poster Presentation Topic: Tumor immunology Citation: Manrique Rincón AJ, Marques Beraldo C, Marcelino Toscaro J, Pereira Vieira De Carvalho AC and Bajgelman MC (2015). OX40 costimulation acts synergistically with GVAX boosting the elimination of tumor cells in a murine melanoma model. Front. Immunol. Conference Abstract: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología. doi: 10.3389/conf.fimmu.2015.05.00067 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 May 2015; Published Online: 14 Sep 2015. * Correspondence: PhD. Marcio C Bajgelman, National Center For Research in Energy and Materials – CNPEM, Brazilian Biosciences National Laboratory– LNBio, CAMPINAS, Sao Paulo, 13083-970, Brazil, marcio.bajgelman@lnbio.cnpem.br Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Andrea J Manrique Rincón Camila Marques Beraldo Jessica Marcelino Toscaro Anna C Pereira Vieira De Carvalho Marcio C Bajgelman Google Andrea J Manrique Rincón Camila Marques Beraldo Jessica Marcelino Toscaro Anna C Pereira Vieira De Carvalho Marcio C Bajgelman Google Scholar Andrea J Manrique Rincón Camila Marques Beraldo Jessica Marcelino Toscaro Anna C Pereira Vieira De Carvalho Marcio C Bajgelman PubMed Andrea J Manrique Rincón Camila Marques Beraldo Jessica Marcelino Toscaro Anna C Pereira Vieira De Carvalho Marcio C Bajgelman Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.